Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Personalized Therapy in Early Breast Cancer
NCT01779206Phase 3Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- May 2012
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin, cyclophosphamide, docetaxel, paclitaxel in breast cancer, sponsored by Westdeutsche Studiengruppe. Started May 2012; status: completed.
02
Drugs
epirubicincyclophosphamidedocetaxelpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01779206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01779206.